Safety and Effectiveness of the Coronary Momo Stent

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-02-29

Study Completion Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the safety and effectiveness of the Momo Cobalt Chromium stent system for the treatment of single de novo lesions in a native coronary artery. The stent is coated with diamond-like carbon to decrease the risk of acute and late stent thrombosis, to increase the resistance towards corrosion and to significantly improve endothelialisation through the inhibition of elution of metallic ions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Treatment of Coronary Artery Lesions Using the PRO-Kinetic Energy Cobalt-Chromium, Bare-Metal Stent

NCT01811927

Coronary Artery Disease

TERMINATED NA

RESOLUTE Japan SVS: The Clinical Evaluation of the MDT-4107 DES in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries

NCT01150500

Arterial Occlusive Diseases Myocardial Ischemia Cardiovascular Diseases +1 more

COMPLETED NA

Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting Cobalt-CHromium Stent

NCT02014818

Coronary Artery Disease

UNKNOWN NA

Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting Cobalt-CHromium Stent and Platelet AggregatioN studIeS for TreatMent of Acute Myocardial InfarctionTreatment of ST-elevation Acute Myocardial Infarction

NCT02014753

Coronary Artery Disease

COMPLETED

Safety and Efficacy Study of Kaname Coronary Stent System for the Treatment of Patients With Coronary Artery Disease

NCT01004575

Coronary Artery Disease Angioplasty, Transluminal, Percutaneous Coronary

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Momo stent

Patients with PCI

Group Type OTHER

Momo stent

Intervention Type DEVICE

Patients with PCI

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Momo stent

Patients with PCI

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with stable angina pectoris (Canadian Cardiovascular Society \[CCS\] I to IV) or unstable angina pectoris (Braunwald classification IB-C, IIB-C or IIIB-C) or patients with documented silent ischemia.
2. Patients who are eligible for coronary revascularization by angioplasty and stenting and by CABG (if required as bail-out).
3. Patients with a de novo lesion in a native coronary artery between \> 50 % and \< 100 % stenosis.
4. One or two heart vessel disease with a maximum of 2 lesions to be treated by stenting.

Both lesions have to be treated with study stents.
5. Target vessel suitable for implantation of a single stent with a target vessel diameter of ≥ 2.5 mm and lesion length \< 20 mm.
6. Patients with left ventricular ejection fraction (LVEF) of \> 30 %.
7. Patients willing to sign a written informed consent prior to participation and willing to be compliant with all requested follow-up evaluations.

Exclusion Criteria

1. Patients under the age of 18 or unable to give informed consent.
2. Women of child bearing potential.
3. Patients who currently participate in another study (whatever the subject of that study is).
4. Patients who participated in another investigational cardiovascular drug or device study, which have not completed the primary endpoint follow-up period within the past 30 days.
5. Patients with a life expectancy of less than 24 months or factors making clinical and/or angiographic follow-up difficult (no fixed address, etc.).
6. Patients who intend to have a major (as per principal investigators' medical judgment) surgical intervention within 6 months of enrolment in the study.
7. Patients with an episode of sustained ischemic chest pain exceeding 15 minutes duration within 24 hours prior to stenting or patients with new ST elevation within 48 hours prior to stenting.
8. Patients with a contraindication to emergency coronary bypass surgery.
9. Any individual who may refuse a blood transfusion.
10. Patients with serum creatinine \> 2.0 mg/dl or (\> 180 µmol/l).
11. Patients with a baseline platelet count less than 100,000 platelets/mm³.
12. Patients with intolerance or contraindication to acetylsalicylic acid (aspirin), heparin, clopidogrel or ticlopidine drug therapy.
13. Patients with contrast agent hypersensitivity that cannot be adequately pre-medicated.
14. Patients whose target vessel has been stented before.
15. Any procedure to treat another coronary artery scheduled within 6 months after implantation of the study stent.

1. Patients with previous PCI of the same segment (i.e. no restenotic lesions).
2. Any previous interventional procedure (less than 6 months) anywhere within the target vessel.
3. Target lesion is located in or supplied by an arterial or venous bypass graft
4. Target lesion involves a side branch ≥ 2.0 mm in diameter.
5. Ostial target lesion (within 3.0 mm of vessel origin).
6. Target vessel has evidence of thrombus or is excessively tortuous that makes it unsuitable for proper stent delivery and deployment.
7. Patients with total occlusions (TIMI 0).
8. Significant (\>50%) stenosis proximal or distal to the target lesion than might require revascularization or impede run off.
9. Target lesion requires treatment with a device other than the predilatation balloon prior to stent placement (including but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, cutting balloon etc.).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No